Our state-of-the-art Plainville facility delivers comprehensive sterile fill-finish and viral vector services, from process development through commercial manufacturing. With exceptional capacity and capabilities, we are fully equipped to meet market demands.
Spanning 290,000 square feet, the site adds additional North American sterile fill-finish development services, with two lines dedicated to final drug product production. It also supports the manufacturing of viral vectors for both clinical and commercial use.
Under one roof, the facility provides process and analytical development, characterization, validation, and clinical and commercial manufacturing. This integrated offering eliminates the need for costly and time-consuming facility-to-facility technology transfers.
Strategically designed for growth, the site can seamlessly accommodate future expansions up to 400,000 square feet, ensuring we continue to meet our clients’ ever-evolving needs.
To learn more about this location, download the site capabilities factsheet.
Blog post
Viral vector commercialization – Part 3: Specialized regulatory support
Find detailed regulatory considerations when preparing viral vectors for commercialization and best practices to address them.
View Blog PostBlog post
Viral vector commercialization – Part 2: Best practices in process validation lifecycle
Learn more about the robust viral vector process validation cycle, which includes various assessments and studies to ensure the safety, efficacy, and quality of viral vectors.
View Blog PostWebinar
Benefits of an integrated approach to gene therapy development and manufacturing
Thermo Fisher Scientific's expert will take you through the development and commercialization of viral vectors for gene therapy, so you can navigate these hurdles and deliver the project in a timely, cost-effective manner. With integrated gene therapy development and manufacturing, you can benefit more than a customized solution. It improves coordination, streamlines decision-making, and uses resources more efficiently.;
View WebinarSite Location
Seneffe, Belgium, Europe
The Seneffe site (34,000 ft2) supports both clinical and commercial manufacturing. This site has over 20 years experience in virus and viral vector manufacturing and has been previously approved by EMA for commercial vaccine production.
View Site Location